Orchard Therapeutics Plc (ORTX) Misses Q3 EPS by 14c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q3 EPS of ($0.37), $0.14 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.78 million versus the consensus estimate of $4.41 million.

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• T. Rowe Price (TROW) PT Raised to $110 at TD Cowen
• Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'